R. Hamacher

Oncologic Staging with 68Ga-FAPI PET/CT Demonstrates a Lower Rate of Nonspecific Lymph Node Findings Than 18F-FDG PET/CT

L. Umutlu, K. Herrmann, K. Pomykala, 2023, The Journal of Nuclear Medicine.

68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial

N. Hirmas, J. Ferdinandus, L. Kessler, 2023, The Journal of Nuclear Medicine.

Detection of tumour heterogeneity in patients with advanced, metastatic castration-resistant prostate cancer on [68Ga]Ga-/[18F]F-PSMA-11/-1007, [68Ga]Ga-FAPI-46 and 2-[18F]FDG PET/CT: a pilot study

C. Kesch, L. Kessler, K. Pomykala, 2024, European Journal of Nuclear Medicine and Molecular Imaging.

Prognostic Implications of 68Ga-FAPI-46 PET/CT–Derived Parameters on Overall Survival in Various Types of Solid Tumors

N. Hirmas, H. Grafe, B. von Tresckow, 2024, The Journal of Nuclear Medicine.

Diagnostic Accuracy of 68Ga-FAPI Versus 18F-FDG PET in Patients with Various Malignancies

N. Hirmas, C. Kesch, L. Kessler, 2024, Journal of Nuclear Medicine.